See more : Cinerad Communications Limited (CINERAD.BO) Income Statement Analysis – Financial Results
Complete financial analysis of KalVista Pharmaceuticals, Inc. (KALV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of KalVista Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Microsoft Corporation (4338.HK) Income Statement Analysis – Financial Results
- Digital Brands Group, Inc. (DBGIW) Income Statement Analysis – Financial Results
- Maruti Infrastructure Limited (MAINFRA.BO) Income Statement Analysis – Financial Results
- Iberdrola, S.A. (IBE1.BE) Income Statement Analysis – Financial Results
- Costamare Inc. (CMRE-PB) Income Statement Analysis – Financial Results
KalVista Pharmaceuticals, Inc. (KALV)
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 12.69M | 12.69M | 16.13M | 8.39M | 1.50M | 2.13M | 1.80M | 415.00K | 1.54M |
| Cost of Revenue | 86.17M | 802.00K | 743.00K | 651.00K | 40.19K | 35.02K | 18.24K | 12.67K | 14.66K | 8.29K | 0.00 | 0.00 |
| Gross Profit | -86.17M | -802.00K | -743.00K | 12.04M | 12.65M | 16.09M | 8.38M | 1.49M | 2.12M | 1.80M | 415.00K | 1.54M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 94.87% | 99.68% | 99.78% | 99.78% | 99.16% | 99.31% | 99.54% | 100.00% | 100.00% |
| Research & Development | 86.17M | 80.28M | 70.17M | 41.29M | 40.19M | 35.02M | 18.24M | 12.67M | 14.66M | 8.29M | 4.23M | 1.96M |
| General & Administrative | 54.28M | 30.60M | 26.45M | 16.64M | 13.03M | 10.93M | 8.86M | 11.18M | 2.65M | 1.61M | 1.40M | 1.41M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 54.28M | 30.60M | 26.45M | 16.64M | 13.03M | 10.93M | 8.86M | 11.18M | 2.65M | 1.61M | 1.40M | 1.41M |
| Other Expenses | -86.17M | 15.64M | 14.72M | 9.93M | 9.83M | 7.68M | 4.39M | 2.33M | 2.03M | 844.00K | -59.00K | 35.00K |
| Operating Expenses | 54.28M | 110.87M | 96.61M | 57.92M | 53.22M | 45.95M | 27.10M | 23.84M | 17.31M | 9.89M | 5.63M | 3.37M |
| Cost & Expenses | 140.45M | 110.87M | 96.61M | 57.92M | 53.22M | 45.95M | 27.10M | 23.84M | 17.31M | 9.89M | 5.63M | 3.37M |
| Interest Income | 0.00 | 2.23M | 1.09M | 903.00K | 1.83M | 1.40M | 82.00K | 36.00K | 50.00K | 19.00K | 2.00K | 1.00K |
| Interest Expense | 0.00 | 0.00 | 1.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 405.00K | 256.00K |
| Depreciation & Amortization | 816.00K | 802.00K | 743.00K | 651.00K | 525.00K | 378.00K | 180.00K | 40.00K | 133.00K | 38.00K | 27.00K | 38.00K |
| EBITDA | -134.28M | -92.11M | -81.60M | -45.59M | -40.02M | -29.44M | -18.53M | -22.30M | -15.15M | -8.05M | -5.25M | -1.76M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -458.89% | -312.48% | -182.87% | -201.94% | -1,573.80% | -788.05% | -446.29% | -1,264.10% | -114.37% |
| Operating Income | -140.45M | -110.87M | -96.61M | -57.92M | -40.53M | -29.82M | -18.71M | -22.34M | -15.18M | -8.09M | -5.22M | -1.83M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -456.45% | -319.41% | -184.91% | -222.84% | -1,485.31% | -711.72% | -448.39% | -1,256.87% | -119.18% |
| Total Other Income/Expenses | 5.35M | 17.96M | 14.27M | 11.68M | 11.29M | 9.13M | 2.90M | 3.74M | 3.75M | 863.00K | -462.00K | -220.00K |
| Income Before Tax | -135.10M | -92.91M | -82.34M | -46.24M | -29.24M | -20.69M | -15.81M | -18.60M | -11.44M | -7.23M | -5.68M | -2.05M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -364.41% | -230.42% | -128.31% | -188.29% | -1,236.90% | -536.15% | -400.55% | -1,368.19% | -133.49% |
| Income Tax Expense | -8.45M | -18.05M | -13.83M | -1.75M | -124.00K | 124.00K | -1.33M | -5.11M | -5.41M | -863.00K | 462.00K | 220.00K |
| Net Income | -126.64M | -74.85M | -68.51M | -44.49M | -29.12M | -20.82M | -15.81M | -18.60M | -11.44M | -7.23M | -5.68M | -2.05M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -350.62% | -229.44% | -129.08% | -188.29% | -1,236.90% | -536.15% | -400.55% | -1,368.19% | -133.49% |
| EPS | -3.44 | -2.68 | -2.80 | -2.33 | -1.64 | -1.38 | -1.53 | -1.92 | -2.40 | -6.17 | -7.83 | -2.83 |
| EPS Diluted | -3.44 | -2.68 | -2.80 | -2.33 | -1.64 | -1.38 | -1.53 | -1.92 | -2.40 | -6.17 | -7.83 | -2.83 |
| Weighted Avg Shares Out | 36.79M | 27.89M | 24.47M | 19.09M | 17.75M | 15.08M | 10.32M | 9.71M | 4.77M | 1.17M | 724.80K | 724.80K |
| Weighted Avg Shares Out (Dil) | 36.79M | 27.89M | 24.47M | 19.09M | 17.75M | 15.08M | 10.32M | 9.71M | 4.77M | 1.17M | 724.80K | 724.80K |
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today released financial results for the second fiscal quarter ended October 31, 2024. The Company also provided an operational update, highlighted by the U.S. Food and Drug Administration (FDA) acceptance...
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista's board of directors granted five newly-hired employees inducement options to purchase an aggregate of 36,000 shares of KalVista common stock on December...
KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Laurence Reid, Ph.D., has been appointed to the Company's Board of Directors, effective immediately. Dr. Reid brings more than three decades of experience with a track record...
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at each of the following investor conferences: Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024, at 9:10 a.m....
KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) (“KalVista”) today announced the pricing of an underwritten offering of 5,500,000 shares of its common stock at a price of $10.00 per share to certain investors (the “Offering”). The gross...
KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) (“KalVista”), today announced the closing of a synthetic royalty financing agreement with DRI Healthcare Trust (“DRI”) for up to $179 million, comprised of a $100 million upfront payment, a one-time...
KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the presentation of new sebetralstat data at the American College of Allergy Asthma and Immunology (ACAAI) taking place in Boston, MA from October 24 - 28, 2024. Tim...
KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that five abstracts have been accepted for e-Poster presentation at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI), taking place in...
KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that it presented data showing the effectiveness of sebetralstat in reducing anxiety among people experiencing hereditary angioedema (HAE) attacks at the HAEi Global Angioedema Forum (GAF) taking place...
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista's board of directors granted six newly-hired employees inducement options to purchase an aggregate of 31,000 shares of KalVista common stock on October...
Source: https://incomestatements.info
Category: Stock Reports